Whitestar can deal with even the hardest nuclei

Article

Microincision cataract surgery (MICS) with the Whitestar ICE and CASE systems (AMO) can be performed safely and effectively even in the hardest nuclei, according to a Turkish study.

Microincision cataract surgery (MICS) with the Whitestar ICE and CASE systems (AMO) can be performed safely and effectively even in the hardest nuclei, according to a Turkish study.

Hasan Oguzhan and colleagues from the Dr Sadi Konuk Education and Research Hospital, Istanbul, Turkey performed MICS on 20 eyes (17 patients) using the Whitestar surgical system with ICE and CASE settings. Patients were selected according to their nucleus hardness (grade 3 – 4) and were examined for intraoperative complications, mean phaco time, total phaco %, effective phaco time (EPT), endothelial cell loss, postoperative corneal oedema and mean uncorrected and best corrected visual acuity.

The mean phaco time, total phaco % and EPT were one minute 24 seconds, 4.8% and 3.22 seconds, respectively. The mean preoperative and postoperative endothelial cell counts and percentage endothelial cell loss were 2 376, 2 253, and 5.2%, respectively. The mean early (within three days) postoperative uncorrected visual acuity and late postoperative best corrected visual acuity were 0.6 and 0.9 on the Snellen chart, respectively. There were no complications and surgery was performed safely in even the hardest nuclei.

It was the conclusion of the authors that bimanual MICS using the Whitestar ICE and CASE systems is both safe and effective even in the hardest nuclei.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.